Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0031 | 0.6159 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0041 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0041 | 1 | 0.5 |
Onchocerca volvulus | 0.0031 | 0.6159 | 0.5 | |
Entamoeba histolytica | hypothetical protein | 0.0041 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.021 | 0.0342 |
Echinococcus granulosus | lamin dm0 | 0.0031 | 0.6159 | 0.6076 |
Brugia malayi | intermediate filament protein | 0.0031 | 0.6159 | 0.5815 |
Echinococcus granulosus | lamin | 0.0031 | 0.6159 | 0.6076 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 1 | 1 |
Onchocerca volvulus | 0.0031 | 0.6159 | 0.5 | |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0821 | 0.1333 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0041 | 1 | 1 |
Echinococcus multilocularis | lamin | 0.0031 | 0.6159 | 0.6076 |
Echinococcus multilocularis | lamin dm0 | 0.0031 | 0.6159 | 0.6076 |
Entamoeba histolytica | hypothetical protein | 0.0041 | 1 | 0.5 |
Echinococcus granulosus | intermediate filament protein | 0.0031 | 0.6159 | 0.6076 |
Loa Loa (eye worm) | hypothetical protein | 0.0031 | 0.5949 | 0.9658 |
Entamoeba histolytica | hypothetical protein | 0.0041 | 1 | 0.5 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0031 | 0.6159 | 1 |
Echinococcus multilocularis | musashi | 0.0031 | 0.6159 | 0.6076 |
Loa Loa (eye worm) | intermediate filament protein | 0.0031 | 0.6159 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0031 | 0.6159 | 0.5815 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0041 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.